2017
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine 2017, 23: 703-713. PMID: 28481359, PMCID: PMC5461196, DOI: 10.1038/nm.4333.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterCancer-related genesProspective clinical sequencingAdvanced solid cancersSequencing platformsStructural variantsGenomic landscapeGenomic mutationsDetailed clinical annotationMutational landscapeSequencing resultsNumber alterationsCancer CenterPatient enrollmentClinical trialsMSK-IMPACTMetastatic cancerSolid cancersNew insightsNormal tissuesClinical sequencingCancer therapyPatientsCancerClinical annotation
2016
Second‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care
Hatzoglou V, Omuro AM, Haque S, Khakoo Y, Ganly I, Oh JH, Shukla-Dave A, Fatovic R, Gaal J, Holodny AI. Second‐opinion interpretations of neuroimaging studies by oncologic neuroradiologists can help reduce errors in cancer care. Cancer 2016, 122: 2708-2714. PMID: 27219108, PMCID: PMC4992439, DOI: 10.1002/cncr.30083.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolDiagnostic ErrorsFemaleFollow-Up StudiesHumansImage Interpretation, Computer-AssistedInfantMagnetic Resonance ImagingMaleMiddle AgedNeoplasm StagingNeoplasmsNeuroimagingObserver VariationPatient CarePhysiciansPrognosisRadiologistsReferral and ConsultationRetrospective StudiesTomography, X-Ray ComputedYoung AdultConceptsSecond-opinion interpretationsPatient managementMagnetic resonance imaging studySecond-opinion radiology reportsResonance imaging studyNational Cancer InstitutePatient ageNeuro-oncologistsCancer CenterDisease stageStudy criteriaCancer patientsClinical assessmentClinical impactNeck surgeonsRetrospective analysisHistopathologic analysisCancer InstituteImaging studiesRadiology reportsOutside reportsReference standardNeuroradiologistsSurgeonsDiscrepant reports
2014
Transcriptional diversity of long-term glioblastoma survivors
Gerber NK, Goenka A, Turcan S, Reyngold M, Makarov V, Kannan K, Beal K, Omuro A, Yamada Y, Gutin P, Brennan CW, Huse JT, Chan TA. Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology 2014, 16: 1186-1195. PMID: 24662514, PMCID: PMC4136896, DOI: 10.1093/neuonc/nou043.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterLong-term survivorsLong-term glioblastoma survivorsIDH mutationsIDH2 mutational statusMedian overall survivalStrong prognostic valueBiology of glioblastomaMGMT promoter methylationMedian survivalOverall survivalBetter prognosisPoor prognosisPrognostic valueCancer CenterAggressive typeIndependent cohortMesenchymal subtypeREMBRANDT cohortMutational statusIDH2 mutationsGBM biologyPatientsMGMT methylationMGMT promoter
2012
Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center
Welch MR, Omuro A, DeAngelis LM. Outcomes of the oldest patients with primary CNS lymphoma treated at Memorial Sloan-Kettering Cancer Center. Neuro-Oncology 2012, 14: 1304-1311. PMID: 22952196, PMCID: PMC3452344, DOI: 10.1093/neuonc/nos207.Peer-Reviewed Original ResearchConceptsMemorial Sloan-Kettering Cancer CenterOlder patientsCancer CenterSurvival rateLower baseline creatinine clearanceMedian progression-free survivalTwo-year survival rateBaseline creatinine clearanceDeep brain involvementSignificant renal toxicityMedian overall survivalPrimary CNS lymphomaProgression-free survivalTertiary care centerHigh-dose MTXPredictors of survivalFifth treatment cycleOcular radiationAggressive therapyCNS lymphomaBrain involvementCreatinine clearanceMost patientsOverall survivalPCNSL patients